Need professional-grade analysis? Visit stockanalysis.com
$729.60M
N/A
N/A
N/A
Kura Oncology Inc (KURA) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $9.47, down 2.17% from the previous close.
Over the past year, KURA has traded between a low of $5.54 and a high of $12.14. The stock has gained 50.1% over this period. It is currently 22.0% below its 52-week high.
Kura Oncology Inc has a market capitalization of $729.60M.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Side-by-side comparison against top Healthcare peers.